ABSCI CORP Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
ABSCI CORP (ABSI) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 2.00% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-03-24
- ABSCI CORP effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2024 was 2.00%, a 5.26% increase from fiscal 2023.
- ABSCI CORP effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2023 was 1.90%, a 20.83% decline from fiscal 2022.
- ABSCI CORP effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2022 was 2.40%, a 300.00% increase from fiscal 2021.
- ABSCI CORP effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2021 was 0.60%, a 500.00% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2024-12-31 | 2.00% 10-K · filed 2026-03-24 |
| 2023-12-31 | 1.90% 10-K · filed 2025-03-18 |
| 2022-12-31 | 2.40% 10-K · filed 2024-03-21 |
| 2021-12-31 | 0.60% 10-K · filed 2023-03-30 |
| 2020-12-31 | 0.10% 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |